Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Non- controlling Interest
Beginning balance at Sep. 30, 2021	$ 408,822	$ 197	$ 1,053,386	$ (69)	$ (644,692)	$ 0
Beginning balance (in shares) at Sep. 30, 2021		104,327,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	24,504		24,504
Exercise of stock options	2,145		2,145
Exercise of stock options (in shares)		208,000
Common stock - restricted stock units vesting (in shares)		263,000
Foreign currency translation adjustments	(39)			(39)
Net loss	(62,872)				(62,872)
Ending balance at Dec. 31, 2021	372,560	$ 197	1,080,035	(108)	(707,564)	0
Ending balance (in shares) at Dec. 31, 2021		104,798,000
Beginning balance at Sep. 30, 2021	408,822	$ 197	1,053,386	(69)	(644,692)	0
Beginning balance (in shares) at Sep. 30, 2021		104,327,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Foreign currency translation adjustments	(71)
Net loss	(90,552)
Ending balance at Jun. 30, 2022	474,177	$ 198	1,189,113	(140)	(735,244)	20,250
Ending balance (in shares) at Jun. 30, 2022		105,795,000
Beginning balance at Dec. 31, 2021	372,560	$ 197	1,080,035	(108)	(707,564)	0
Beginning balance (in shares) at Dec. 31, 2021		104,798,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	33,802		33,802
Exercise of stock options	1,537		1,537
Exercise of stock options (in shares)		237,000
Common stock - restricted stock units vesting	0	$ 1	(1)
Common stock - restricted stock units vesting (in shares)		667,000
Foreign currency translation adjustments	1			1
Net loss	44,366				44,366
Ending balance at Mar. 31, 2022	452,266	$ 198	1,115,373	(107)	(663,198)	0
Ending balance (in shares) at Mar. 31, 2022		105,702,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	33,391		33,391
Exercise of stock options	599		599
Exercise of stock options (in shares)		53,000
Common stock - restricted stock units vesting (in shares)		40,000
Foreign currency translation adjustments	(33)			(33)
Net loss	(72,046)				(72,046)
Ending balance at Jun. 30, 2022	474,177	$ 198	1,189,113	(140)	(735,244)	20,250
Ending balance (in shares) at Jun. 30, 2022		105,795,000
Beginning balance at Sep. 30, 2022	418,339	$ 198	1,219,213	(136)	(820,755)	19,819
Beginning balance (in shares) at Sep. 30, 2022		105,960,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	19,390		19,390
Exercise of stock options	576		576
Exercise of stock options (in shares)		82,000
Common stock - restricted stock units vesting	0	$ 1	(1)
Common stock - restricted stock units vesting (in shares)		98,000
Foreign currency translation adjustments	(122)			(122)
Interest in joint venture	(486)					(486)
Net loss	(41,325)				(41,325)
Ending balance at Dec. 31, 2022	396,372	$ 199	1,239,178	(258)	(862,080)	19,333
Ending balance (in shares) at Dec. 31, 2022		106,140,000
Beginning balance at Sep. 30, 2022	$ 418,339	$ 198	1,219,213	(136)	(820,755)	19,819
Beginning balance (in shares) at Sep. 30, 2022		105,960,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	343,801
Foreign currency translation adjustments	$ (275)
Net loss	(95,596)
Ending balance at Jun. 30, 2023	381,985	$ 199	1,281,393	(411)	(916,351)	17,155
Ending balance (in shares) at Jun. 30, 2023		107,102,000
Beginning balance at Dec. 31, 2022	396,372	$ 199	1,239,178	(258)	(862,080)	19,333
Beginning balance (in shares) at Dec. 31, 2022		106,140,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	20,612		20,612
Exercise of stock options	520		520
Exercise of stock options (in shares)		64,000
Common stock - restricted stock units vesting (in shares)		665,000
Foreign currency translation adjustments	(74)			(74)
Interest in joint venture	(999)					(999)
Net loss	48,675				48,675
Ending balance at Mar. 31, 2023	465,106	$ 199	1,260,310	(332)	(813,405)	18,334
Ending balance (in shares) at Mar. 31, 2023		106,869,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	19,947		19,947
Exercise of stock options	1,136		1,136
Exercise of stock options (in shares)		198,000
Common stock - restricted stock units vesting (in shares)		35,000
Foreign currency translation adjustments	(79)			(79)
Interest in joint venture	(1,179)					(1,179)
Interest in joint venture	60,000		39,750			20,250
Net loss	(102,946)				(102,946)
Ending balance at Jun. 30, 2023	$ 381,985	$ 199	$ 1,281,393	$ (411)	$ (916,351)	$ 17,155
Ending balance (in shares) at Jun. 30, 2023		107,102,000